AAPL   374.40 (+2.83%)
MSFT   210.65 (+2.13%)
FB   238.74 (+2.28%)
AMZN   3,013.94 (+4.28%)
NVDA   394.61 (+2.63%)
CGC   16.76 (+1.88%)
MU   50.94 (+2.23%)
TSLA   1,326.77 (+9.77%)
AMD   53.15 (+1.55%)
ACB   12.23 (-0.33%)
DIS   113.51 (+1.19%)
BAC   23.50 (+0.90%)
NFLX   496.73 (+4.16%)
BA   182.10 (+0.71%)
AAPL   374.40 (+2.83%)
MSFT   210.65 (+2.13%)
FB   238.74 (+2.28%)
AMZN   3,013.94 (+4.28%)
NVDA   394.61 (+2.63%)
CGC   16.76 (+1.88%)
MU   50.94 (+2.23%)
TSLA   1,326.77 (+9.77%)
AMD   53.15 (+1.55%)
ACB   12.23 (-0.33%)
DIS   113.51 (+1.19%)
BAC   23.50 (+0.90%)
NFLX   496.73 (+4.16%)
BA   182.10 (+0.71%)
AAPL   374.40 (+2.83%)
MSFT   210.65 (+2.13%)
FB   238.74 (+2.28%)
AMZN   3,013.94 (+4.28%)
NVDA   394.61 (+2.63%)
CGC   16.76 (+1.88%)
MU   50.94 (+2.23%)
TSLA   1,326.77 (+9.77%)
AMD   53.15 (+1.55%)
ACB   12.23 (-0.33%)
DIS   113.51 (+1.19%)
BAC   23.50 (+0.90%)
NFLX   496.73 (+4.16%)
BA   182.10 (+0.71%)
AAPL   374.40 (+2.83%)
MSFT   210.65 (+2.13%)
FB   238.74 (+2.28%)
AMZN   3,013.94 (+4.28%)
NVDA   394.61 (+2.63%)
CGC   16.76 (+1.88%)
MU   50.94 (+2.23%)
TSLA   1,326.77 (+9.77%)
AMD   53.15 (+1.55%)
ACB   12.23 (-0.33%)
DIS   113.51 (+1.19%)
BAC   23.50 (+0.90%)
NFLX   496.73 (+4.16%)
BA   182.10 (+0.71%)
Log in

OTCMKTS:CYDYCytoDyn Stock Price, Forecast & News

$6.08
-0.40 (-6.17 %)
(As of 07/6/2020 12:18 PM ET)
Add
Compare
Today's Range
$5.90
Now: $6.08
$7.15
50-Day Range
$2.81
MA: $3.69
$8.77
52-Week Range
$0.26
Now: $6.08
$10.01
Volume9.48 million shs
Average Volume6.36 million shs
Market Capitalization$3.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.59
CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. CytoDyn Inc. is based in Vancouver, Washington.
Read More
CytoDyn logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.83 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYDY
Previous SymbolNASDAQ:CYDY
CUSIP23283M101
Phone360-980-8524

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.03) per share

Profitability

Net Income$-56,190,000.00

Miscellaneous

Employees6
Market Cap$3.22 billion
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

How has CytoDyn's stock been impacted by COVID-19 (Coronavirus)?

CytoDyn's stock was trading at $1.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYDY shares have increased by 490.3% and is now trading at $6.08. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CytoDyn?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for CytoDyn.

When is CytoDyn's next earnings date?

CytoDyn is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for CytoDyn.

How were CytoDyn's earnings last quarter?

CytoDyn Inc (OTCMKTS:CYDY) announced its quarterly earnings data on Thursday, April, 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.02. View CytoDyn's earnings history.

What price target have analysts set for CYDY?

1 analysts have issued 1-year price objectives for CytoDyn's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate CytoDyn's share price to reach $4.00 in the next twelve months. This suggests that the stock has a possible downside of 34.2%. View analysts' price targets for CytoDyn.

Has CytoDyn been receiving favorable news coverage?

News stories about CYDY stock have been trending negative this week, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CytoDyn earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about CytoDyn.

Who are some of CytoDyn's key competitors?

What other stocks do shareholders of CytoDyn own?

Who are CytoDyn's key executives?

CytoDyn's management team includes the following people:
  • Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 56)
  • Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 67)
  • Dr. Denis R. Burger, Scientific Consultant (Age 75)
  • Dr. Richard G. Pestell M.B.A., M.D., MBA. M.D., Ph.D., Vice Chairman & Chief Medical Officer
  • Dr. Nitya G. Ray, Chief Technology Officer & Head of Process Sciences, Manufacturing and Supply Chain (Age 66)

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $6.08.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $3.22 billion. The biotechnology company earns $-56,190,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. CytoDyn employs 6 workers across the globe.

What is CytoDyn's official website?

The official website for CytoDyn is www.cytodyn.com.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.